FDA selects vaccines for 2025-2026 US influenza season
The US Food and Drug Administration (FDA) has announced its recommendations to vaccine manufacturers for the virus strains to be used in influenza (flu) vaccines for the 2025-2026 US flu season following a thorough and comprehensive review of US and global surveillance data.
With today’s action, the FDA said it does not anticipate any impact on timing or availability of vaccines for the American public. The recommendations are similar to the previous year’s strain selection.
The announcement comes after the abrupt cancellation of the vaccines advisory committee meeting that had been scheduled for March 13, and raised concerns that manufacturers would not have sufficient time to produce the vaccines ahead of the upcoming flu season.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze